Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients

Journal of Human Genetics

Volumn 56, Issue 4, 2011, Pages 290-295

  Choi, Jung Ran ^a,g   Kim, Jeong Oh ^a   Kang, Dae Ryong ^b   Yoon, Seong Ae ^a   Shin, Jung Young ^a   Zhang, XiangHua ^a   Roh, Mee Ork ^c   Hong, Hyung Joo ^c   Wang, Young Pil ^c   Jo, Keon Hyon ^c   Lee, Kwang Soo ^c   Yun, Ho Jung ^c   Oh, Yong Seog ^c   Yoo, Ki Dong ^d   Jeon, Hee Gyeong ^e   Lee, Yoon Sook ^f   Kang, Tae Sun ^f   Park, Hyun Joo ^f   Chung, Myeon Woo ^f   Kang, Jin Hyoung ^a,c  

^a The Catholic University of Korea   (South Korea)

^b Yonsei University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Uijeongbu St Mary's Hospital   (South Korea)

^f Korea Food and Drug Administration   (South Korea)

^g Ewha Womans University   (South Korea)

Author keywords

CYP2C9; CYP4F2; dosing algorithm; pharmacogenetics; VKORC1; warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ALGORITHM; ANTICOAGULATION; ARTICLE; BODY SURFACE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE AND SEX; HUMAN; INTERNATIONAL NORMALIZED RATIO; KOREA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BODY SIZE; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MODELS, BIOLOGICAL; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; SEX FACTORS; WARFARIN;

EID: 79955486891     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2011.4     Document Type: Article

References (24)

1. Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005). (Pubitemid 41510803)
2. Wang, T. L., Li, H. L., Tjong, W. Y., Chen, Q. S., Wu, G. S., Zhu, H. T. et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin. Chim. Acta. 396, 76-79 (2008).
3. Pchelina, S. N., Sirotkina, O. V., Taraskina, A. E., Vavilova, T. V., Shwarzman, A. L. & Schwartz, E. I. The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy. Thromb. Res. 115, 199-203 (2005). (Pubitemid 40029676)
4. Kimura, R., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K. et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120, 181-186 (2007). (Pubitemid 46754413)
5. Miao, L., Yang, J., Huang, C. & Shen, Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur. J. Clin. Pharmacol. 63, 1135-1141 (2007). (Pubitemid 350112769)
6. Roper, N., Storer, B., Bona, R. & Fang, M. Validation and comparison of pharmacogenetics- based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn. 12, 283-291 (2010).
7. Wen, M. S., Lee, M., Chen, J. J., Chuang, H. P., Lu, L. S., Chen, C. H. et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84, 83-89 (2008). (Pubitemid 351861488)
8. Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. T. et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827-3834 (2010).
9. Villagra, D., Duconge, J., Windemuth, A., Cadilla, C. L., Kocherla, M., Gorowski, K. et al. CYP2C9 and VKORC1 genotypes in Puerto Ricans: a case for admixture-matching in clinical pharmacogenetic studies. Clin. Chim. Acta. 6, 1306-1311 (2010).
10. Sagreiya, H., Berube, C., Wen, A., Ramakrishnan, R., Mir, A., Hamilton, A. et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP29. Pharmacogenet. Genomics 20, 407-413 (2010).
11. Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
12. Patrinos, G. P. & Innocenti, F. Pharmacogenomics: paving the path to personalized medicine. Pharmacogenomics 11, 141-146 (2010).
13. Jonas, D. E. & McLeod, L Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol. Sci. 30, 375-386 (2009).
14. Langley, M. R., Booker, J. K., Evans, J. P., McLeod, H. L. & Weck, K. E. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J. Mol. Diagn. 11, 216-225 (2009).
15. D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005). (Pubitemid 40070748)
16. Lal, S., Jada, S. R., Xiang, X., Lim, W. T., Lee, E. J. & Chowbay, B. Pharmacogenetics of target genes across the warfarin pharmacological pathway. Clin. Pharmacokinet. 45, 1189-1200 (2006). (Pubitemid 44904822)
17. Yin, T. & Miyata, T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1-rationale and perspectives. Thromb. Res. 120, 1-10 (2007). (Pubitemid 46601582)
18. Rieder, M. J., Reiner, A. P. & Rettie, A. E. g-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J. Thromb. Haemost. 5, 2227-2234 (2007). (Pubitemid 47617875)
19. Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005). (Pubitemid 41131718)
20. Carlquist, J. F., Horne, B. D., Muhlestein, J. B., Lappé , D. L., Whiting, B. M., Kolek, M. J. et al. Genotypes of the cytochrome P450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22, 191-197 (2006). (Pubitemid 44857780)
21. Ozer, N., Cam, N., Tangurek, B., Ozer, S., Uyarel, H., Oz, D. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels 25, 155-162 (2010).
22. Cho, H. J., Sohn, K. H., Park, H. M., Lee, K. H., Choi, B., Kim, S. et al. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8, 329-337 (2007). (Pubitemid 46585496)
23. Takeuchi, F., Kashida, M., Okazaki, O., Tanaka, Y., Fukuda, S., Kashima, T. et al. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ. J. 74, 977-982 (2010).
24. Bodin, L., Verstuyft, C., Tregouet, D. A., Robert, A., Dubert, L., Funck-Brentano, C. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106, 135-140 (2005). (Pubitemid 40967184)